Barclays
CERE

Barclays’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Barclays’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-25,500
Closed -$1.08M – 5437
2023
Q4 		$1.08M Buy
+25,500
New +$733K ﹤0.01% 3385

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Barclays's CERE Position: Q3 2024 in Review

Barclays sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 50,865 shares — an estimated $2.08M sold.

Barclays first reported a position in CERE in Q1 2022 and held it in 10 quarters. The position peaked at $14.9M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Barclays reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Barclays sold 50,865 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $2.08M.
  • Barclays first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2022 and held it in 10 quarters.
  • Barclays's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $14.9M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Barclays's 13F filing for Q3 2024, filed 15 Nov 2024.